143 related articles for article (PubMed ID: 36800273)
1. Breast Cancer and Physiologic Avidity From Breast Feeding on FDG PET/CT.
Ulaner GA
Clin Nucl Med; 2023 May; 48(5):420-421. PubMed ID: 36800273
[TBL] [Abstract][Full Text] [Related]
2. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
4. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
6. Primary Breast Lymphoma Mimicking Metastatic Breast Cancer on 18F-FDG PET-CT.
Usmani S; Albader FL; Marafi F; Elhaggracy RS
J Pak Med Assoc; 2022 Jun; 72(6):1241-1242. PubMed ID: 35751349
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application.
Chakraborty D; Basu S; Ulaner GA; Alavi A; Kumar R
PET Clin; 2018 Jul; 13(3):355-361. PubMed ID: 30100075
[TBL] [Abstract][Full Text] [Related]
8. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Systemic Staging (Comparison of Computed Tomography, Bone Scan, and 18F-Fluorodeoxyglucose PET/Computed Tomography).
Groheux D
PET Clin; 2023 Oct; 18(4):503-515. PubMed ID: 37268506
[TBL] [Abstract][Full Text] [Related]
10. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
12. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
13. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
14. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
15. Comparison of
Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
[TBL] [Abstract][Full Text] [Related]
16. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
[TBL] [Abstract][Full Text] [Related]
17. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
Seo MJ; Lee JJ; Kim HO; Chae SY; Park SH; Ryu JS; Ahn SH; Lee JW; Son BH; Gong GY; Moon DH
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):438-45. PubMed ID: 24196918
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer.
Groheux D
Semin Nucl Med; 2022 Sep; 52(5):508-519. PubMed ID: 35636977
[TBL] [Abstract][Full Text] [Related]
19. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
Cermik TF; Mavi A; Basu S; Alavi A
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):475-83. PubMed ID: 17957366
[TBL] [Abstract][Full Text] [Related]
20. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
